Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRD NYSE:OSTX NASDAQ:PMCB NASDAQ:RVPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRDOpus Genetics$1.13+0.9%$0.99$0.65▼$2.18$67.42M-0.02618,848 shs190,573 shsOSTXOS Therapies$1.70+1.8%$1.77$1.12▼$7.00$47.77MN/A490,693 shs344,012 shsPMCBNuvilex$1.09-0.6%$1.07$1.00▼$2.42$7.48M-0.4219,683 shs21,611 shsRVPHReviva Pharmaceuticals$0.39-0.2%$0.74$0.30▼$4.28$18.78M-0.061.47 million shs2.73 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRDOpus Genetics+0.90%+12.00%+9.80%+58.08%+111,999,900.00%OSTXOS Therapies+0.60%-10.70%-14.80%+33.60%+166,999,900.00%PMCBNuvilex-1.21%-0.40%+1.54%-2.52%-46.77%RVPHReviva Pharmaceuticals+0.54%+6.52%-53.33%-41.90%-66.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRDOpus Genetics1.5557 of 5 stars3.50.00.00.01.20.00.6OSTXOS Therapies1.8856 of 5 stars3.70.00.00.00.01.70.6PMCBNuvilex1.5691 of 5 stars0.05.00.00.00.60.81.9RVPHReviva Pharmaceuticals2.613 of 5 stars3.62.00.00.00.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRDOpus Genetics 3.00Buy$7.33548.97% UpsideOSTXOS Therapies 3.40Buy$18.00958.82% UpsidePMCBNuvilex 0.00N/AN/AN/ARVPHReviva Pharmaceuticals 3.29Buy$9.002,200.61% UpsideCurrent Analyst Ratings BreakdownLatest PMCB, RVPH, OSTX, and IRD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/27/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/27/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.006/24/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/9/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/3/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.005/20/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $3.005/15/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/24/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/22/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/11/2025IRDOpus GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRDOpus Genetics$10.99M6.13N/AN/A$0.21 per share5.38OSTXOS TherapiesN/AN/AN/AN/AN/AN/APMCBNuvilexN/AN/AN/AN/A$3.27 per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRDOpus Genetics-$57.53M-$2.10N/AN/AN/A-429.42%-283.28%-144.32%8/12/2025 (Estimated)OSTXOS Therapies-$7.79M-$0.86N/AN/AN/AN/AN/A-569.57%N/APMCBNuvilex$330K$0.741.47∞N/AN/A0.51%0.35%8/11/2025 (Estimated)RVPHReviva Pharmaceuticals-$29.92M-$0.79N/AN/AN/AN/AN/A-302.31%8/13/2025 (Estimated)Latest PMCB, RVPH, OSTX, and IRD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IRDOpus Genetics-$0.34-$0.32+$0.02-$0.24$4.00 million$4.30 million5/15/2025Q1 2025RVPHReviva Pharmaceuticals-$0.21-$0.13+$0.08-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRDOpus GeneticsN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/APMCBNuvilexN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRDOpus GeneticsN/A1.981.98OSTXOS TherapiesN/A0.760.76PMCBNuvilexN/A14.2114.21RVPHReviva PharmaceuticalsN/A0.540.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRDOpus Genetics14.97%OSTXOS TherapiesN/APMCBNuvilex34.24%RVPHReviva Pharmaceuticals63.18%Insider OwnershipCompanyInsider OwnershipIRDOpus Genetics6.60%OSTXOS Therapies13.80%PMCBNuvilex10.20%RVPHReviva Pharmaceuticals27.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRDOpus Genetics1459.66 million55.72 millionN/AOSTXOS TherapiesN/A28.10 millionN/AN/APMCBNuvilex46.86 million6.16 millionOptionableRVPHReviva Pharmaceuticals548.00 million34.96 millionOptionablePMCB, RVPH, OSTX, and IRD HeadlinesRecent News About These CompaniesReviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Recommendation of "Buy" by AnalystsJuly 5, 2025 | americanbankingnews.comReviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.comJune 29, 2025 | investing.comReviva Dives on Stock OfferingJune 26, 2025 | baystreet.caReviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public OfferingJune 26, 2025 | globenewswire.comReviva Pharmaceuticals stock falls after announcing public offeringJune 25, 2025 | za.investing.comReviva Pharmaceuticals Holdings, Inc. Announces Proposed Public OfferingJune 25, 2025 | globenewswire.comRVPH: Open Label Extension Results & Key Opinion Leader DiscussionJune 5, 2025 | finance.yahoo.comReviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 5, 2025 | globenewswire.comReviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaJune 2, 2025 | globenewswire.comReviva to Participate in Upcoming Investor Conferences in May 2025May 20, 2025 | santelog.comSReviva Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 15, 2025 | globenewswire.comReviva to Participate in the A.G.P. Healthcare Company ShowcaseMay 13, 2025 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)May 4, 2025 | theglobeandmail.comReviva to Participate in the Citizens Life Sciences ConferenceApril 29, 2025 | finance.yahoo.comRVPH: M&A Deals Highlight Brilaroxazine ValueApril 7, 2025 | finance.yahoo.comRoth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)April 5, 2025 | markets.businessinsider.comReviva Reports Full Year 2024 Financial Results and Recent Business HighlightsMarch 31, 2025 | markets.businessinsider.comReviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS CongressMarch 30, 2025 | globenewswire.comWhy Reviva Pharmaceuticals Holdings, Inc.’s (RVPH) Stock Is Down 10.61%March 7, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimePMCB, RVPH, OSTX, and IRD Company DescriptionsOpus Genetics NASDAQ:IRD$1.13 +0.01 (+0.89%) Closing price 04:00 PM EasternExtended Trading$1.11 -0.02 (-1.77%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.OS Therapies NYSE:OSTX$1.70 +0.03 (+1.80%) Closing price 04:00 PM EasternExtended Trading$1.70 +0.01 (+0.29%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.Nuvilex NASDAQ:PMCB$1.09 -0.01 (-0.60%) Closing price 03:59 PM EasternExtended Trading$1.10 +0.00 (+0.46%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Reviva Pharmaceuticals NASDAQ:RVPH$0.39 0.00 (-0.20%) Closing price 04:00 PM EasternExtended Trading$0.40 +0.01 (+3.53%) As of 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
